Newsbenzinga
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
· Published
Article summary
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
An excerpt from the original article.
Comments —
Loading comments…